Details for Patent: 9,393,256
✉ Email this page to a colleague
Which drugs does patent 9,393,256 protect, and when does it expire?
Patent 9,393,256 protects HARVONI and is included in two NDAs.
Protection for HARVONI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-five patent family members in forty-one countries.
Summary for Patent: 9,393,256
| Title: | Methods for treating HCV |
| Abstract: | This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions. |
| Inventor(s): | Ray; Adrian S. (Burlingame, CA), Link; John O. (San Francisco, CA), Oldach; David W. (Chapel Hill, NC), Delaney, IV; William E. (Foster City, CA), Mo; Hongmei (Palo Alto, CA), Yang; Cheng Yong (Foster City, CA) |
| Assignee: | Gilead Pharmasset LLC (Foster City, CA) |
| Application Number: | 13/875,252 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,393,256 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 9,393,256
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-002 | Aug 28, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-002 | Aug 28, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,393,256
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 088580 | ⤷ Sign Up | |||
| Argentina | 089578 | ⤷ Sign Up | |||
| Australia | 2012308295 | ⤷ Sign Up | |||
| Australia | 2012332827 | ⤷ Sign Up | |||
| Australia | 2012346217 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
